200 related articles for article (PubMed ID: 30499639)
1. Impact of empirical treatment with antifungal agents on survival of patients with candidemia.
Poves-Alvarez R; Cano-Hernández B; Muñoz-Moreno MF; Balbás-Alvarez S; Román-García P; Gómez-Sánchez E; Martínez-Rafael B; Gómez-Pesquera E; Lorenzo-López M; Alvarez-Fuente E; de la Varga O; Flores M; Eiros JM; Tamayo E; Heredia-Rodríguez M
Rev Esp Quimioter; 2019 Feb; 32(1):6-14. PubMed ID: 30499639
[TBL] [Abstract][Full Text] [Related]
2. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort.
López-Cortés LE; Almirante B; Cuenca-Estrella M; Garnacho-Montero J; Padilla B; Puig-Asensio M; Ruiz-Camps I; Rodríguez-Baño J;
Clin Microbiol Infect; 2016 Aug; 22(8):733.e1-8. PubMed ID: 27189197
[TBL] [Abstract][Full Text] [Related]
3. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
[TBL] [Abstract][Full Text] [Related]
4. Initial antifungal strategy does not correlate with mortality in patients with candidemia.
Murri R; Scoppettuolo G; Ventura G; Fabbiani M; Giovannenze F; Taccari F; Milozzi E; Posteraro B; Sanguinetti M; Cauda R; Fantoni M
Eur J Clin Microbiol Infect Dis; 2016 Feb; 35(2):187-93. PubMed ID: 26634352
[TBL] [Abstract][Full Text] [Related]
5. Antifungal treatment with echinocandins: a 10-year clinical experience.
Poves-Alvarez R; Cano-Hernández B; Balbás-Alvarez S; Román-García P; Heredia-Rodríguez M; Gómez-Sánchez E; Gómez-Pesquera E; Lorenzo-López M; Martínez-Rafael B; Muñoz-Moreno MF; Eiros JM; Tamayo E
Rev Esp Quimioter; 2017 Dec; 30(6):413-421. PubMed ID: 29141400
[TBL] [Abstract][Full Text] [Related]
6. Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study.
Micek ST; Arnold H; Juang P; Hampton N; McKenzie M; Scolarici M; Kollef M
Clin Ther; 2014 Sep; 36(9):1226-32. PubMed ID: 25064625
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis.
Lin KY; Chen PY; Chuang YC; Wang JT; Sun HY; Sheng WH; Chen YC; Chang SC
J Infect; 2018 Sep; 77(3):242-248. PubMed ID: 29932963
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
[TBL] [Abstract][Full Text] [Related]
9. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
Wade RL; Chaudhari P; Campbell RS; Hays HD; Nathanson BH; Yi J; Horn D
J Med Econ; 2012; 15(6):1130-8. PubMed ID: 22788668
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
Bienvenu AL; Pradat P; Guerin C; Aubrun F; Fellahi JL; Friggeri A; Guichon C; Hernu R; Menotti J; Monard C; Paulus S; Rimmele T; Piriou V; Chidiac C; Argaud L; Leboucher G
Int J Infect Dis; 2020 Apr; 93():15-21. PubMed ID: 31982622
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.
Eschenauer GA; Carver PL; Lin SW; Klinker KP; Chen YC; Potoski BA; Shields RK; Clancy CJ; Nguyen MH; Lam SW
J Antimicrob Chemother; 2013 Apr; 68(4):922-6. PubMed ID: 23212115
[TBL] [Abstract][Full Text] [Related]
14. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
[TBL] [Abstract][Full Text] [Related]
15. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis.
Cuervo G; Garcia-Vidal C; Puig-Asensio M; Vena A; Meije Y; Fernández-Ruiz M; González-Barberá E; Blanco-Vidal MJ; Manzur A; Cardozo C; Gudiol C; Montejo JM; Pemán J; Ayats J; Aguado JM; Muñoz P; Marco F; Almirante B; Carratalà J;
Clin Infect Dis; 2017 May; 64(10):1374-1379. PubMed ID: 28329281
[TBL] [Abstract][Full Text] [Related]
16. The Effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected].
De Rosa FG; Corcione S; Filippini C; Raviolo S; Fossati L; Montrucchio C; Aldieri C; Petrolo A; Cavallo R; Di Perri G
PLoS One; 2015; 10(5):e0125149. PubMed ID: 25938486
[TBL] [Abstract][Full Text] [Related]
17. Attributable mortality of candidemia after introduction of echinocandins.
Cornely FB; Cornely OA; Salmanton-García J; Koehler FC; Koehler P; Seifert H; Wingen-Heimann S; Mellinghoff SC
Mycoses; 2020 Dec; 63(12):1373-1381. PubMed ID: 32885534
[TBL] [Abstract][Full Text] [Related]
18. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Girão E; Levin AS; Basso M; Gobara S; Gomes LB; Medeiros EA; Costa SF
Med Mycol; 2008 Sep; 46(6):581-8. PubMed ID: 19180727
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
Tadec L; Talarmin JP; Gastinne T; Bretonnière C; Miegeville M; Le Pape P; Morio F
Mycoses; 2016 May; 59(5):296-303. PubMed ID: 26806101
[TBL] [Abstract][Full Text] [Related]
20. Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.
Eschenauer GA; Nguyen MH; Clancy CJ
Ann Pharmacother; 2015 Sep; 49(9):1068-74. PubMed ID: 26104051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]